

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



XMD17-109

Item No. 25448

CAS Registry No.: 1435488-37-1

Formal Name: 11-cyclopentyl-2-[[2-ethoxy-4-[[4-(4-


> methyl-1-piperazinyl)-1-piperidinyl]carbonyl] phenyl]amino]-5,11-dihydro-5-methyl-6Hpyrimido[4,5-b][1,4]benzodiazepin-6-one

Synonym: ERK5-IN-1 MF: $C_{36}H_{46}N_8O_3$ FW: 638.8 **Purity:** ≥98%

 λ_{max} : 285, 312 nm UV/Vis.: A crystalline solid Supplied as:

-20°C Storage: ≥2 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

XMD17-109 is supplied as a crystalline solid. A stock solution may be made by dissolving the XMD17-109 in the solvent of choice. XMD17-109 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of XMD17-109 in these solvents is approximately 1 mg/ml.

Description

XMD17-109 is a selective ERK5 inhibitor (IC₅₀ = $0.162 \mu M$ in an enzyme assay). It is selective for ERK5 over a panel of more than 200 kinases, inhibiting only ERK5 with greater than 90% target occupancy at a concentration of 10 μ M. XMD17-109 inhibits ERK5 phosphorylation (IC $_{50}$ = 0.09 μ M in HeLa cells) and decreases AP-1 transcriptional activity (EC₅₀ = $4.2 \mu M$).² It also inhibits human recombinant LRRK2[G2019S], which contains a mutation that has been linked to Parkinson's disease, with an IC_{50} value of 0.339 μM in an enzyme assay.1

References

- 1. Deng, X., Elkins, J.M., Zhang, J., et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur. J. Med. Chem. 70, 758-767
- 2. Elkins, J.M., Wang, J., Deng, X., et al. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. J. Med. Chem. 56(11), 4413-4421 (2013).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 08/15/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM